670 related articles for article (PubMed ID: 35870128)
1. Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19).
Li H; Gao M; You H; Zhang P; Pan Y; Li N; Qin L; Wang H; Li D; Li Y; Qiao H; Gu L; Xu S; Guo W; Wang N; Liu C; Gao P; Niu J; Cao J; Zheng Y
Clin Infect Dis; 2023 Feb; 76(3):e148-e154. PubMed ID: 35870128
[TBL] [Abstract][Full Text] [Related]
2. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
[TBL] [Abstract][Full Text] [Related]
3. Nirmatrelvir and ritonavir combination against COVID-19 caused by omicron BA.2.2 in the elderly: A single-center large observational study.
Chen C; Li R; Xing S; Cao L; Qu Y; Lv Q; Li X; Chen Z
Immun Inflamm Dis; 2024 Apr; 12(4):e1232. PubMed ID: 38578027
[TBL] [Abstract][Full Text] [Related]
4. [Related factors of viral nucleic acid change in critically ill patients with SARS-CoV-2 infection after treatment with Nirmatrelvir/Ritonavir: a single center retrospective cohort study].
Yan M; Xie M; Zhu S; Li H; Li S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Nov; 35(11):1150-1156. PubMed ID: 37987124
[TBL] [Abstract][Full Text] [Related]
5. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
Cao Z; Gao W; Bao H; Feng H; Mei S; Chen P; Gao Y; Cui Z; Zhang Q; Meng X; Gui H; Wang W; Jiang Y; Song Z; Shi Y; Sun J; Zhang Y; Xie Q; Xu Y; Ning G; Gao Y; Zhao R
N Engl J Med; 2023 Feb; 388(5):406-417. PubMed ID: 36577095
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY
Lancet Infect Dis; 2023 Jul; 23(7):806-815. PubMed ID: 36933565
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
[TBL] [Abstract][Full Text] [Related]
8. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
[TBL] [Abstract][Full Text] [Related]
10. Short-Term Effectiveness of Oral Nirmatrelvir/Ritonavir Against the SARS-CoV-2 Omicron Variant and Culture-Positive Viral Shedding.
Lee E; Park S; Choi JP; Kim MK; Yang E; Ham SY; Lee S; Lee B; Yang JS; Park BK; Kim DS; Lee SY; Lee JY; Jang HC; Jeon J; Park SW
J Korean Med Sci; 2023 Feb; 38(8):e59. PubMed ID: 36852855
[TBL] [Abstract][Full Text] [Related]
11. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
Epling BP; Rocco JM; Boswell KL; Laidlaw E; Galindo F; Kellogg A; Das S; Roder A; Ghedin E; Kreitman A; Dewar RL; Kelly SEM; Kalish H; Rehman T; Highbarger J; Rupert A; Kocher G; Holbrook MR; Lisco A; Manion M; Koup RA; Sereti I
Clin Infect Dis; 2023 Feb; 76(4):573-581. PubMed ID: 36200701
[TBL] [Abstract][Full Text] [Related]
12. Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study.
Rajme-López S; Martinez-Guerra BA; Román-Montes CM; Tamez-Torres KM; Tello-Mercado AC; Tepo-Ponce KM; Segura-Ortíz Z; López-Aguirre A; Gutiérrez-Mazariegos ODR; Lazcano-Delgadillo O; Nares-López R; González-Lara MF; Kershenobich-Stalnikowitz D; Sifuentes-Osornio J; Ponce-de-León A; Ruíz-Palacios GM
Ther Adv Infect Dis; 2024; 11():20499361241236582. PubMed ID: 38545451
[TBL] [Abstract][Full Text] [Related]
13. Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir.
Martin-Blondel G; Marcelin AG; Soulié C; Kaisaridi S; Lusivika-Nzinga C; Zafilaza K; Dorival C; Nailler L; Boston A; Ronchetti AM; Melenotte C; Cabié A; Choquet C; Trinh-Duc A; Lacombe K; Gaube G; Coustillères F; Pourcher V; Martellosio JP; Peiffer-Smadja N; Chauveau M; Housset P; Piroth L; Devaux M; Pialoux G; Martin A; Dubee V; Frey J; Le Bot A; Cazanave C; Petua P; Liblau R; Carrat F; Yordanov Y
Clin Microbiol Infect; 2023 Apr; 29(4):543.e5-543.e9. PubMed ID: 36586513
[TBL] [Abstract][Full Text] [Related]
14. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients.
Piñana JL; Heras I; Aiello TF; García-Cadenas I; Vazquez L; Lopez-Jimenez J; Chorão P; Aroca C; García-Vidal C; Arroyo I; Soler-Espejo E; López-Corral L; Avendaño-Pita A; Arrufat A; Garcia-Gutierrez V; Arellano E; Hernández-Medina L; González-Santillana C; Morell J; Hernández-Rivas JÁ; Rodriguez-Galvez P; Mico-Cerdá M; Guerreiro M; Campos D; Navarro D; Cedillo Á; Martino R; Solano C;
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896843
[TBL] [Abstract][Full Text] [Related]
15. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
[TBL] [Abstract][Full Text] [Related]
16. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
[TBL] [Abstract][Full Text] [Related]
17. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
Saravolatz LD; Depcinski S; Sharma M
Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
[TBL] [Abstract][Full Text] [Related]
18. Real-World Effectiveness of Nirmatrelvir-Ritonavir and Its Acceptability in High-Risk COVID-19 Patients.
Kim MK; Lee KS; Ham SY; Choi YY; Lee E; Lee S; Lee B; Jeon J; Chin B; Kim Y; Kim G; Jang HC; Choi JP; Park SW
J Korean Med Sci; 2023 Sep; 38(35):e272. PubMed ID: 37667578
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
[TBL] [Abstract][Full Text] [Related]
20. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
Sutanto ST; Sinto R; Pasaribu A; Shakinah S
Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
